Figma Shares Indicated To Open $105/$110
On Thursday, RBC Capital Markets began covering Alkermes shares with a Sector Perform rating and established a price target of $40.00. According to InvestingPro data, this aligns with the broader analyst consensus, as the stock currently maintains a "Buy" recommendation with targets ranging from $21 to $46. The research firm’s assessment acknowledges the potential of Alkermes’ next-generation orexin antagonist for treating narcolepsy, which they believe could achieve sales exceeding $1.5 billion and provide a clearer view of the company’s long-term growth prospects.
The statement from RBC Capital Markets suggests that while the new orexin antagonist might lead the market, the narcolepsy treatment space is becoming increasingly competitive. The firm is awaiting further data that could help estimate the maximum market opportunity for the drug. The analysts note the current challenges faced by Alkermes, including a downturn in its base business, operational expenses weighed down by clinical and commercial investments, and a trading value reflecting a balance of near-term earnings pressure against the potential for substantial long-term profitability.
Alkermes, listed on (NASDAQ:ALKS), is valued at a $5 billion enterprise value (EV) and trades at a 15.1x P/E ratio. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 3.04x. RBC Capital’s initiation of coverage reflects a cautious optimism, considering the current valuation as fair given the mix of immediate financial pressures and the possibility of future lucrative opportunities.
The firm’s analysis suggests that Alkermes’ stock price currently accounts for the immediate challenges while also factoring in the potential for significant revenue from its developmental treatments. RBC Capital Markets’ position indicates a watchful stance as they look for additional data to further assess the drug’s prospects in the context of a competitive market and the company’s overall financial health. InvestingPro subscribers have access to 13 additional ProTips and a comprehensive analysis of Alkermes’ financial health, which currently rates as GREAT with a score of 3.64 out of 5, offering deeper insights into the company’s investment potential.
In other recent news, Alkermes reported robust financial results for the fourth quarter of 2024, exceeding both earnings per share (EPS) and revenue forecasts. The company’s EPS was $1.05, surpassing the expected $0.75, while revenue reached $430 million, beating the anticipated $380.75 million. Goldman Sachs responded by raising Alkermes’ stock price target from $30.00 to $32.00, maintaining a Buy rating, highlighting the company’s strong performance and strategic execution. Cantor Fitzgerald also maintained an Overweight rating with a $43.00 target, underscoring the stock’s value proposition and potential pipeline expansion. Jefferies reiterated its Buy rating, setting a $41.00 price target, noting the company’s better-than-expected 2025 guidance. Alkermes’ strategic focus on its Orexin agonist pipeline, particularly the ALKS2680 asset, is attracting significant attention, with Phase 2 data for narcolepsy types 1 and 2 expected in the second half of 2025. The company’s commitment to advancing its pipeline and exploring new opportunities continues to garner confidence from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.